Journal
ARTHRITIS RESEARCH & THERAPY
Volume 6, Issue 2, Pages 41-44Publisher
BMC
DOI: 10.1186/ar1151
Keywords
bias; cohort study; confounding; data banks; randomized controlled trial; rheumatoid arthritis
Categories
Funding
- NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR043584] Funding Source: NIH RePORTER
- NIAMS NIH HHS [AR43584, P01 AR043584] Funding Source: Medline
Ask authors/readers for more resources
Observational databanks have inherent strengths and shortcomings. As in randomized controlled trials, poor design of these databanks can either exaggerate or reduce estimates of drug effectiveness and can limit generalizability. This commentary highlights selected aspects of study design, data collection and statistical analysis that can help overcome many of these inadequacies. An international metaRegister and a formal mechanism for standardizing and sharing drug data could help improve the utility of databanks. Medical journals have a vital role in enforcing a quality checklist that improves reporting.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available